Wegovy (semaglutide 2.4mg) is FDA-approved for chronic weight management and is increasingly covered by insurance plans, though coverage remains inconsistent. As of 2026, more employers and insurers are adding anti-obesity medication coverage, but Medicare still does not cover weight loss drugs. Wegovy costs approximately $1,300 to $1,400 per month without insurance.
Key Facts
For 2027, Medicare's negotiated price for Ozempic, Rybelsus and Wegovy is $274 for a 30-day supply, down from a $959 list price (CMS). Negotiation sets the price, not which uses Part D covers. See all 15 negotiated prices against list.
Check Your Specific Plan's Formulary
Coverage varies by plan. Use our formulary checker tool to look up your exact copay and restrictions.
Open Formulary CheckerAs an Amazon Associate I earn from qualifying purchases.
Gear GLP-1 users buy most
As an Amazon Associate I earn from qualifying purchases.
Sources and standards behind this page
Drug coverage in the United States is governed by published rules rather than by any one insurer's summary, and the sources below are the primary ones. They are linked so a reader can check a claim without taking this page's word for it.
- FDA Orange Book publishes the therapeutic-equivalence ratings that decide whether a generic may be substituted for a brand-name drug.
- FDA generic drug facts sets out what "generic equivalent" means and what a manufacturer must prove.
- CMS prescription drug coverage defines the rules a Medicare drug plan formulary must follow and how it may change mid-year.
- Medicare.gov drug coverage (Part D) states what a Part D plan is required to offer a member.
- CMS prescription drug appeals documents the coverage-determination and exception process when a drug is denied.
This page describes how coverage and formularies work. It is not medical advice, and a reader's own plan documents and prescriber decide what applies to them.
Frequently Asked Questions
No. Federal law currently prohibits Medicare Part D from covering drugs used for weight loss. Even though Wegovy received an additional FDA indication for cardiovascular risk reduction in 2024, Medicare coverage for the weight loss indication remains excluded. Legislative efforts to change this are ongoing but have not passed as of 2026.
Check if your plan covers anti-obesity medications. If so, your doctor must submit prior authorization documenting your BMI, weight-related conditions, and any failed lifestyle interventions. If your plan does not cover weight loss drugs, ask HR (for employer plans) about adding coverage, or consider plans that include it during open enrollment.
Ozempic and Wegovy both contain semaglutide but have different FDA approvals. Ozempic is approved for type 2 diabetes and is widely covered by insurance for that use. Wegovy is approved for weight management and has more limited coverage. They cannot be substituted for each other at the pharmacy, and insurance will only cover the one matching your diagnosis.
Related Resources
- UnitedHealthcare Formulary 2026
- Blue Cross Blue Shield Formulary 2026
- Aetna Formulary 2026
- Ozempic cash price comparison on RxGrab
- Zepbound cash price comparison on RxGrab
- Mounjaro cash price comparison on RxGrab
- Saxenda cash price comparison on RxGrab
- Contrave cash price comparison on RxGrab
- Ozempic patient assistance program
- Patient assistance programs
- Mounjaro patient assistance program
- Drug interaction checker tool
- Patient assistance program finder
Get Formulary and Coverage Updates
Leave your email for alerts on formulary changes, new drug approvals, and insurance coverage updates. We have not started sending yet, and we will only email when we do.